ProCE Banner Activity

Phase I/II CheckMate 032: Nivolumab ± Ipilimumab in Advanced SCLC

Slideset Download
Conference Coverage
Nivolumab with or without ipilimumab associated with durable responses in patients with advanced, previously treated SCLC.

Released: June 07, 2017

Expiration: June 06, 2018

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants by

AbbVie

Amgen, Inc.

AstraZeneca

Celgene

Genentech Roche Virology

Halozyme

Incyte

Merck Oncology